Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS
Campaign Kicks Off with Events at AIDS Walk Los Angeles and Greater
Palm Springs Pride as Well as Digital Ads on More Than 25
The campaign (keep-your-pants-on.com),
which was launched to the 10,000 participants in the AIDS Walk Los
Angeles event on
“Honestly, talking about HIV-related diarrhea isn’t usually on the list
of preferred dinner topics, but after spending too much time sitting on
the toilet pondering a less lousy time, I decided I was ready to keep my
pants on and talk about the subject with my doctor and anybody else that
will listen. And I’m glad I did,” said
Mytesi® is the first and only antidiarrheal approved by the
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding planned, potential follow-on indications for Mytesi®. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
KCSA Strategic Communications
Garth Russell, 212-896-1250